echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Lancet Infect Dis: The safety and immunogenicity of the SARS-CoV-2 inactivated vaccine BBIBP-CorV

    Lancet Infect Dis: The safety and immunogenicity of the SARS-CoV-2 inactivated vaccine BBIBP-CorV

    • Last Update: 2021-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The ongoing COVID-19 pandemic requires accelerated testing of candidate vaccines


    COVID-19 immunity

    In the first phase, healthy people aged 18-80 were included in the study.


    Screening

     

    The results showed that in the first stage, 192 participants (average age 53-7 years [SD 15-6]) were randomly assigned to receive the vaccine (2μg[n=24], 4μg[n=24], or 8μg[n =24], two age groups [18-59 years old and ≥60 years old]) or placebo (n=24)


     

    In Phase 2, 448 participants (mean age 41.


    In summary, the SARS-CoV-2 inactivated vaccine BBIBP-CorV is safe and well tolerated in all doses tested in both age groups


     

    Original source:

     

    Shengli Xia, Yuntao Zhang, et al.


    Safety and immunogenicity of an inactivated SARS- CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.